Atcc htb 26

MDA-MB-231 (ATCC® HTB-26™) was provided by Professor James Lorens (University of Bergen, Bergen, Norway), and MDA-MB-468 (ATCC® HTB-132™) was obtained from the American Type Culture Collection (Manassas, VA., USA). The MDA-MB-231 cells were fingerprinted before use and matched with the cell line MDA-MB-231 (ATCC® HTB-26™) in the ATCC database. MDA-MB-231 was used at passage number five to nine, while the MDA-MB-468 cells were used at passage number two to five. These TNBC cell lines have high tumor take in SCID mice and slowly forming tumors, which may be more stromal dependent than more rapidly growing xenografts. Wild type (WT) and integrin α11-deficient (α11-KO) mouse embryonic fibroblasts (MEFs) were obtained from mouse embryos of embryonic day 14.5 as described previously [31 (link)]. In order to obtain immortalized MEFs, primary MEF cultures were infected with recombinant retrovirus-transducing simian virus 40 (SV40) [32 (link)]. All cell lines were grown in Nutrient Mixture F-12 Ham (Sigma-Aldrich, Steinheim, Germany) supplemented with 10% Foetal Bovine Serum, 100 units/ml penicillin, 100 μg/ml streptomycin, and 1–2% L-glutamine (all from Sigma-Aldrich). The cells were grown as single monolayers in a humidified incubator at 37 °C in 5% CO₂ and in all experiments used at log phase. All cell lines tested negative for mycoplasma contamination.

The MDA-MB-231 human breast cancer cell line (ATCC^® HTB-26, ATCC, Manassas, VA, USA) and HT-29 cells human colorectal cancer (Addexbio/San Diego, CA, USA) cells were cultured in Roswell Park Memorial Institute (RPMI) and Mccoy’s media medium (Sigma-Aldrich Co., St. Louis, MI, USA), supplemented with 10% FBS and 1% penicillin/streptomycin, respectively. All cell lines were incubated under humidified air and 5% CO₂ at 37 °C for further studies.

According to the response to the advanced breast cancer after treatment with lapatinib based molecular targeted therapy from the breast clinic of The Affilicated Huaian No.1 People’s Hospital of Nanjing Medical University were divided into two groups: 27 drug-resistant patients and 21 drug-sensitive patients followed by the collection of tissues samples. Written informed consent was signed from each participant. Also our experiment was approved by the Ethics Committee of The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University.
Normal human mammary epithelial cell line (MCF-10A: ATCC^® CCL-10317), and human breast cancer cell lines (MDA-MB-231: ATCC^® HTB-26 and MCF-7: ATCC^® HTB-22) were provided by the American Type Culture Collection (ATCC, Manassas, VA, USA). At 37°C with an atmosphere of 5% CO₂ in the incubator, cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Rockville, MD, USA) with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA). In addition, LR breast cancer cell lines (MDA-MB-231/LR and MCF-7/LR cells) were established from parental cells through gradual exposure to increasing lapatinib (Sigma-Aldrich, St. Louis, MO, USA) concentrations (for 5 to 250 nM) as previously described (18 (link)).